EICHOR
● Active Not Recruiting
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Condition: Advanced or Metastatic Solid Tumors · Sponsor: Innate Pharma
About this study
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (7)
| Massachusetts General Hospital - Boston | Boston, Massachusetts, United States | — |
| John Theurer Cancer Center | Hackensack, New Jersey, United States | — |
| Mount Sinai Tisch Cancer Center | New York, New York, United States | — |
| NEXT Oncology - Dallas | Dallas, Texas, United States | — |
| NEXT Oncology - Virginia | Fairfax, Virginia, United States | — |
| Centre Léon Bérard | Lyon, France | — |
| Gustave Roussy Cancer Institute | Villejuif, France | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06781983